Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Adenocarcinoma Esophagus: early-phase trial registry

1 of 2 indexed Adenocarcinoma Esophagus trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Adenocarcinoma Esophagus: 2 US clinical trials tracked, 1 recruiting.

Adenocarcinoma Esophagus is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sakti Chakrabarti, running 1 of these trials.

Enrollment posture brief

Registry condition adenocarcinoma-esophagus

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Adenocarcinoma Esophagus (th…50%
Open-enrollment share among volume-matched conditions near Adenocarcinoma Esophagus

Adenocarcinoma Esophagus lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adenocarcinoma Esophagus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adenocarcinoma Esophagus is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Top Sponsors

Named interventions

Most-linked intervention names on Adenocarcinoma Esophagus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sequential FLOT followed by chemoradiation Drug
1 trials
Concurrent Radiation Radiation
1 trials
Vactosertib Drug
1 trials
Standard of Care Chemotherapy Drug
1 trials

US sites by state

Facility locations filed on Adenocarcinoma Esophagus trials. A trial with sites in several states counts in each.

Ohio 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adenocarcinoma Esophagus page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Adenocarcinoma Esophagus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sakti Chakrabarti sponsors the most Adenocarcinoma Esophagus trials on record, review their full trial history before evaluating a specific study. See Sakti Chakrabarti's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma Esophagus condition card totals 2 registered trials; most-linked intervention Sequential FLOT followed by chemoradiation; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.